Terns Pharmaceuticals 미래 성장

Future 기준 확인 0/6

Terns Pharmaceuticals 의 수익은 연간 10.2% 감소할 것으로 예상되는 반면, 연간 수익은 63.6% 로 증가할 것으로 예상됩니다. 63.6% 연간. EPS는 연간 5.4% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 -71.6% 로 예상됩니다.

주요 정보

-10.2%

수익 성장률

-5.4%

EPS 성장률

Pharmaceuticals 수익 성장	17.0%
매출 성장률	63.6%
향후 자기자본 수익률	-71.6%
애널리스트 커버리지	Good
마지막 업데이트	13 Mar 2025

최근 미래 성장 업데이트

Recent updates

Terns Pharma: I Don't See The Positioning

Feb 08

We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth

Feb 06

Terns Pharmaceuticals: Another Potential GLP-1 Entrant

Oct 21

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

Sep 25

Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive

Sep 10

We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth

Aug 18

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

May 03

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

Jan 12

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Sep 29

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Jun 06

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Feb 21

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Oct 03

Terns Pharmaceuticals: The Easy Money Has Been Made

Sep 20

Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08

Aug 08

Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?

Jun 14

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Mar 16

We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate

Nov 24

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Aug 24

Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study

Jun 14

수익 및 매출 성장 예측

NasdaqGS:TERN - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	6	-156	-107	-144	6
12/31/2026	1	-139	-115	-128	7
12/31/2025	N/A	-118	-97	-107	9
12/31/2024	N/A	-93	-87	-82	9
9/30/2024	N/A	-88	-75	-75	N/A
6/30/2024	N/A	-96	-79	-79	N/A
3/31/2024	N/A	-91	-76	-76	N/A
12/31/2023	N/A	-90	-67	-67	N/A
9/30/2023	N/A	-85	-59	-59	N/A
6/30/2023	N/A	-72	-52	-52	N/A
3/31/2023	N/A	-68	-50	-50	N/A
12/31/2022	N/A	-60	-49	-49	N/A
9/30/2022	1	-59	-49	-49	N/A
6/30/2022	1	-54	-44	-43	N/A
3/31/2022	1	-51	-41	-41	N/A
12/31/2021	1	-50	-42	-42	N/A
9/30/2021	N/A	-35	-39	-39	N/A
6/30/2021	N/A	-35	-37	-37	N/A
3/31/2021	N/A	-34	-37	-37	N/A
12/31/2020	N/A	-29	-30	-30	N/A
9/30/2020	N/A	-40	-33	-32	N/A
12/31/2019	N/A	-69	-67	-66	N/A

애널리스트 미래 성장 예측

수입 대 저축률: TERN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: TERN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: TERN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: TERN 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: TERN 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: TERN (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/03/17 04:38
장 마감 주가	2025/03/17 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Terns Pharmaceuticals, Inc. 13 애널리스트 중 9 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Etzer Darout	BMO Capital Markets Equity Research
Evan Seigerman	BMO Capital Markets Equity Research
Corinne Johnson	Goldman Sachs

Terns Pharmaceuticals 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 9.5% to US$18.07

Price target increased by 16% to US$16.50

Price target decreased by 8.9% to US$13.93

Price target decreased by 7.4% to US$14.29

Price target increased by 8.8% to US$16.14

Price target increased by 7.5% to US$14.83

Recent updates

Terns Pharmaceuticals Provides Program Updates and Announces Participation At Td Cowen 45Th Annual Healthcare Conference

Terns Pharmaceuticals, Inc. Announces Board of Director Changes

Terns Pharma: I Don't See The Positioning

We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth

New major risk - Shareholder dilution

Independent Director notifies of intention to sell stock

New minor risk - Insider selling

CEO & Director recently bought US$110k worth of stock

Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia

Terns Pharmaceuticals, Inc. Announces Board Changes

Terns Pharmaceuticals: Another Potential GLP-1 Entrant

Price target increased by 9.5% to US$18.07

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

Independent Director recently bought US$5.0m worth of stock

Independent Director exercised options and sold US$141k worth of stock

Terns Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150.149762 million.

Terns Pharmaceuticals, Inc. Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive

Price target increased by 16% to US$16.50

Terns Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth

Terns Pharmaceuticals, Inc. Announces Transition of Mark Vignola as Chief Financial Officer, Effective Until the End of January 2025

Terns Pharmaceuticals, Inc. Presents New Preclinical Data Supporting TERN-501 in Combination with A GLP-1R Agonist for Obesity

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

Terns Pharmaceuticals, Inc. Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor Tern-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation

Terns Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2024

Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer

New major risk - Revenue and earnings growth

Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans

Price target decreased by 8.9% to US$13.93

Price target decreased by 7.4% to US$14.29

New minor risk - Share price stability

Terns Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

New major risk - Revenue and earnings growth

Terns Pharmaceuticals, Inc. Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-ß Agonist TERN-501 in NASH

Terns Pharmaceuticals, Inc. Announces Leadership Transition

Terns Pharmaceuticals, Inc. Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Price target increased by 8.8% to US$16.14

Price target increased by 7.5% to US$14.83

Price target increased by 9.5% to US$13.80

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Price target increased by 33% to US$11.50

Price target increased to US$8.67

Price target increased to US$6.67

High number of new and inexperienced directors

Terns Pharmaceuticals, Inc. Highlights Results from Phase 1 Clinical Trial of Tern-501 At AASLD The Liver Meeting® 2022

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Price target increased to US$6.67

Terns Pharmaceuticals: The Easy Money Has Been Made

Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08

Terns Pharmaceuticals, Inc. Announces Appointment of Radhika Tripuraneni to Board of Directors

Terns Pharmaceuticals, Inc.(NasdaqGS:TERN) dropped from Russell 2500 Value Index

Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress 2022

Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?

Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer

No longer forecast to breakeven

Terns Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

High number of new and inexperienced directors

Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth

Forecast to breakeven in 2024

We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate

Co-Founder & Executive Officer notifies of intention to sell stock

Terns Pharmaceuticals, Inc. Completes Part 1 Enrollment of Aviation Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely

Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

Terns Pharmaceuticals, Inc. Reports Positive Top-Line Results from Phase 2a Lift Study of FXR Agonist TERN-101 in Patients with NASH

Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study